ANI Pharmaceuticals develops, manufactures, and markets generic and branded specialty pharmaceuticals, with a notable presence in areas such as rare diseases, corticosteroids, and other niche therapeutic categories. It operates its own manufacturing capabilities to supply finished dose products to the U.S. market. The company sells primarily through wholesale, retail pharmacy, and specialty distribution channels rather than direct-to-consumer brands.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 211.4 | — | 7.3 | — |
| Q3 2025 | 227.8 | — | 26.3 | — |
| Q4 2025 | 247.1 | — | 20.5 | — |
| Q1 2026 | 237.5 | — | 29.5 | — |
| Q2 2026 | 266 | 25.9% | 23 | 214.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Weibo Corporation (WB), Liberty Latin America Ltd. (LILAK), Suncrete, Inc. (RMIX), Bank First Corporation (BFC), Perella Weinberg Partners (PWP), Photronics, Inc. (PLAB)